Cognition Therapeutics Inc
CGTX
Company Profile
Business description
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Contact
2500 Westchester Avenue
PurchaseNY10577
USAT: +1 412 481-2210
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,369.30 | 4.70 | -0.06% |
| CAC 40 | 7,674.14 | 53.79 | -0.70% |
| DAX 40 | 23,042.92 | 301.62 | -1.29% |
| Dow JONES (US) | 41,218.83 | 98.60 | -0.24% |
| FTSE 100 | 8,578.94 | 17.41 | -0.20% |
| HKSE | 22,662.71 | 158.03 | 0.70% |
| NASDAQ | 17,844.24 | 133.49 | -0.74% |
| Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
| NZX 50 Index | 12,421.09 | 0.16 | -0.00% |
| S&P 500 | 5,650.38 | 36.29 | -0.64% |
| S&P/ASX 200 | 8,151.40 | 6.40 | -0.08% |
| SSE Composite Index | 3,316.11 | 37.08 | 1.13% |